Apr 12, 2022 / 05:30PM GMT
Mike Matson - Needham & Company, LLC - Analyst
Thanks for joining us again at the 21st Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the medtech equity research team here at Needham & Company. I am pleased to introduce Lucid Diagnostics. We have Lucid's CEO, Lishan Aklog; CFO, Dennis McGrath; and VP of Investor Relations, Adrian Miller.
Instead of a standard presentation, we are going to do a Q&A session. If you have any questions you would like me to ask, you can submit them electronically through the Needham conference website or feel free to email them to me at [email protected]. And I'll do my best to fit them in.
So as I noted, we are going to go straight into Q&A here.
Questions and Answers:
Mike Matson - Needham & Company, LLC - AnalystSo we'll start with EsoGuard. You've developed this innovative test and sample collection system for esophageal precancer, called EsoGuard and EsoCheck. It was wondering if you could give us an overview of esophageal cancer, why it's so deadly, and what
Trustpilot
